PDF herunterladen
CC BY 4.0 · Journal of Digestive Endoscopy 2024; 15(03): 169-173
DOI: 10.1055/s-0044-1789011
Research Article

Adenoma Detection Rate after Positive Stool-Based Screening in a U.S. Population

Thilini Delungahawatta 
1   Department of Medicine, MedStar Union Memorial Hospital, Baltimore, Maryland, United States
,
Richard Hum
2   Department of Medicine, Georgetown University School of Medicine, Washington, District of Columbia, United States
,
Stephanie M. Woo
3   Department of Gastroenterology, MedStar Georgetown University Hospital, Washington, District of Columbia, United States
,
Thomas Loughney
3   Department of Gastroenterology, MedStar Georgetown University Hospital, Washington, District of Columbia, United States
,
Joseph Jennings
3   Department of Gastroenterology, MedStar Georgetown University Hospital, Washington, District of Columbia, United States
› Institutsangaben Funding None declared.
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Introduction and Objectives Over the past two decades, advancements in screening programs have led to a decrease in the incidence and mortality rates of colorectal cancer. The recommended benchmark for primary screening colonoscopy adenoma detection rate (ADR) is 25%. However, recent research supports higher ADR benchmarks following positive stool testing. Findings from a Dutch screening program have suggested higher ADRs in fecal immunochemical test positive patients with an inverse relationship with interval cancer development. Our study aims to assess ADRs in a U.S. patient population with positive stool screenings and investigate any correlation to occurrences of interval cancers.

Materials and Methods Data from all positive stool-based screening participants who subsequently underwent colonoscopy at a tertiary care center between 2017 and 2021 were collected. A retrospective chart review was performed to determine the ADR and interval colon cancers.

Results From a total of 120 patients (32 fecal occult blood test [FOBT] positive patients, 43 fecal immunochemical test [FIT] positive patients, 45 FIT-DNA-positive patients), the average ADR was 35%. Nonadvanced polyps were the most identified adenomas at 78.6%. No interval colorectal cancer cases were identified. There was a clear difference in ADR between stool-testing methods, with FIT-DNA showing higher ADRs than FIT and FOBT.

Conclusion Endoscopists should recognize the importance of higher ADR targets in colonoscopies conducted after positive stool-based screening as a means to maintain high-quality colonoscopy standards.

Keywords

adenoma detection rate - colonoscopy - colorectal cancer - colorectal neoplasms - stool-based screening

Previous Presentation

American College of Gastroenterology Annual Scientific Meeting in Vancouver, Canada in October 2023.


Statement of Ethics

Approval from the Institutional Review Board was obtained before conducting the chart review.


Author Contributions

T.D. was responsible for planning of the study, collecting and interpreting of data, as well as drafting and editing of the manuscript. R.H. was responsible for collecting data and drafting of the manuscript. S.M.W. was responsible for planning of the study, data analysis, as well as editing of the manuscript. T.L. and J.J. were involved with planning of the study and revision of manuscript. All the authors have approved the final draft of the manuscript submitted.




Publikationsverlauf

Artikel online veröffentlicht:
27. August 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Gupta S. Screening for colorectal cancer. Hematol Oncol Clin North Am 2022; 36 (03) 393-414
    CrossrefPubMedSuche in Google Scholar
  • 2 Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin 2023; 73 (03) 233-254
    CrossrefPubMedSuche in Google Scholar
  • 3 Chan SCH, Liang JQ. Advances in tests for colorectal cancer screening and diagnosis. Expert Rev Mol Diagn 2022; 22 (04) 449-460
    CrossrefPubMedSuche in Google Scholar
  • 4 Gross CP, Andersen MS, Krumholz HM, McAvay GJ, Proctor D, Tinetti ME. Relation between Medicare screening reimbursement and stage at diagnosis for older patients with colon cancer. JAMA 2006; 296 (23) 2815-2822
    CrossrefPubMedSuche in Google Scholar
  • 5 Rex DK, Boland CR, Dominitz JA. et al. Colorectal cancer screening: recommendations for physicians and patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol 2017; 112 (07) 1016-1030
    CrossrefPubMedSuche in Google Scholar
  • 6 Kaminski MF, Regula J, Kraszewska E. et al. Quality indicators for colonoscopy and the risk of interval cancer. N Engl J Med 2010; 362 (19) 1795-1803
    CrossrefPubMedSuche in Google Scholar
  • 7 Kaminski MF, Thomas-Gibson S, Bugajski M. et al. Performance measures for lower gastrointestinal endoscopy: a European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative. Endoscopy 2017; 49 (04) 378-397
    CrossrefPubMedSuche in Google Scholar
  • 8 Corley DA, Jensen CD, Marks AR. et al. Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med 2014; 370 (14) 1298-1306
    CrossrefPubMedSuche in Google Scholar
  • 9 Wisse PHA, Erler NS, de Boer SY. et al. Adenoma detection rate and risk for interval postcolonoscopy colorectal cancer in fecal immunochemical test-based screening : a population-based cohort study. Ann Intern Med 2022; 175 (10) 1366-1373
    CrossrefPubMedSuche in Google Scholar
  • 10 Rex DK, Petrini JL, Baron TH. et al; ASGE/ACG Taskforce on Quality in Endoscopy. Quality indicators for colonoscopy. Am J Gastroenterol 2006; 101 (04) 873-885
    CrossrefPubMedSuche in Google Scholar
  • 11 Issa IA, Noureddine M. Colorectal cancer screening: an updated review of the available options. World J Gastroenterol 2017; 23 (28) 5086-5096
    CrossrefPubMedSuche in Google Scholar
  • 12 Wong JCT, Chiu HM, Kim HS. et al; Asia-Pacific Working Group on Colorectal Cancer. Adenoma detection rates in colonoscopies for positive fecal immunochemical tests versus direct screening colonoscopies. Gastrointest Endosc 2019; 89 (03) 607-613.e1
    CrossrefPubMedSuche in Google Scholar
  • 13 Denis B, Gendre I, Tuzin N. et al. Adenoma detection rate is enough to assess endoscopist performance: a population-based observational study of FIT-positive colonoscopies. Endosc Int Open 2022; 10 (09) E1208-E1217
    Thieme ConnectPubMedSuche in Google Scholar
  • 14 Mohan BP, Khan SR, Daugherty E. et al. Pooled rates of adenoma detection by colonoscopy in asymptomatic average-risk individuals with positive fecal immunochemical test: a systematic review and meta-analysis. Gastrointest Endosc 2022; 96 (02) 208-222.e14
    CrossrefPubMedSuche in Google Scholar
  • 15 Robertson DJ, Lee JK, Boland CR. et al. Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2017; 152 (05) 1217-1237.e3
    CrossrefPubMedSuche in Google Scholar
  • 16 Jover R, Herráiz M, Alarcón O. et al; Spanish Society of Gastroenterology, Spanish Society of Gastrointestinal Endoscopy Working Group. Clinical practice guidelines: quality of colonoscopy in colorectal cancer screening. Endoscopy 2012; 44 (04) 444-451
    Thieme ConnectPubMedSuche in Google Scholar
  • 17 Waldmann E, Kammerlander AA, Gessl I. et al. Association of adenoma detection rate and adenoma characteristics with colorectal cancer mortality after screening colonoscopy. Clin Gastroenterol Hepatol 2021; 19 (09) 1890-1898
    CrossrefPubMedSuche in Google Scholar
  • 18 Wolf AMD, Fontham ETH, Church TR. et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin 2018; 68 (04) 250-281
    CrossrefPubMedSuche in Google Scholar
  • 19 Young GP, Symonds EL, Allison JE. et al. Advances in fecal occult blood tests: the FIT revolution. Dig Dis Sci 2015; 60 (03) 609-622
    CrossrefPubMedSuche in Google Scholar
  • 20 Imperiale TF, Ransohoff DF, Itzkowitz SH. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 2014; 371 (02) 187-188
    CrossrefPubMedSuche in Google Scholar
  • 21 Adler A, Geiger S, Keil A. et al. Improving compliance to colorectal cancer screening using blood and stool based tests in patients refusing screening colonoscopy in Germany. BMC Gastroenterol 2014; 14: 183
    CrossrefPubMedSuche in Google Scholar
  • 22 Heckroth M, Eiswerth M, Elmasry M. et al. Serrated polyp detection rate in colonoscopies performed by gastrointestinal fellows. Ther Adv Gastrointest Endosc 2022; 15: 26 317745221136775
    Suche in Google Scholar
  • 23 Huang J, Chan PSF, Pang TWY. et al. Rate of detection of serrated lesions at colonoscopy in an average-risk population: a meta-analysis of 129,001 individuals. Endosc Int Open 2021; 9 (03) E472-E481
    Thieme ConnectPubMedSuche in Google Scholar
  • 24 Garg R, Burke CA, Aggarwal M. et al. Sessile serrated polyp detection rates after fecal immunochemical test or multitarget stool DNA test: systematic review and meta-analysis. Endosc Int Open 2024; 12 (04) E474-E487
    Thieme ConnectPubMedSuche in Google Scholar